

PERKINS DISCOVERY FUND

Schedule of Investments

June 30, 2022 (unaudited)

	<u>Shares</u>	<u>Fair Value</u>
95.21% COMMON STOCKS		
2.06% BIOTECHNOLOGY		
Journey Medical Corp.*	22,000	\$ 82,280
MDXHealth SA*	11,000	91,850
		<u>174,130</u>
6.48% CONSUMER DISCRETIONARY		
iMedia Brands, Inc.*	35,700	43,197
Magnite, Inc.*	20,000	177,600
Perion Network Ltd.*	18,000	327,240
		<u>548,037</u>
1.00% FINANCIALS		
FlexShopper, Inc.*	93,500	84,122
		<u>84,122</u>
16.87% HEALTH CARE DRUGS/SERVICES		
ANI Pharmaceuticals, Inc.*	8,000	237,360
NeoGenomics, Inc.*	22,000	179,300
Paratek Pharmaceuticals, Inc.*	36,000	69,480
Sharps Compliance Corp.*	25,000	73,000
Veracyte, Inc.*	21,500	427,850
Vericel Corp.*	17,500	440,650
		<u>1,427,640</u>
5.31% HEALTH CARE MANUFACTURING		
AtriCure, Inc.*	11,000	449,460
		<u>449,460</u>
14.18% HEALTH CARE SUPPLIES		
Axogen, Inc.*	32,500	266,175
Biolase, Inc.*	12,500	57,250
BioLife Solutions, Inc.*	16,500	227,865
Cardiovascular Systems, Inc.*	17,000	244,120
Cryoport, Inc.*	10,000	309,800
Exagen, Inc.*	16,500	94,710
		<u>1,199,920</u>
11.17% HEALTH CARE SUPPORT		
Natera, Inc.*	11,500	407,560
Option Care Health, Inc.*	18,500	514,115
Rockwell Medical, Inc.*	18,182	23,455
		<u>945,130</u>

PERKINS DISCOVERY FUND

Schedule of Investments - continued

June 30, 2022 (unaudited)

	<u>Shares</u>	<u>Fair Value</u>
8.95% HEALTH CARE TECHNOLOGY		
Fortress Biotech, Inc.*	69,500	\$ 58,373
IsoRay, Inc.*	200,000	61,800
OptimizeRx Corp.*	15,000	410,850
Streamline Health Solutions, Inc.*	145,000	184,150
UpHealth, Inc.*	71,250	42,215
		<u>757,388</u>
0.43% INDUSTRIAL		
Agrify Corp.*	18,500	<u>36,445</u>
18.80% INFORMATION TECHNOLOGY		
Airgain, Inc.*	15,500	125,860
Akoustis Technologies, Inc.*	30,500	112,850
Cantaloupe, Inc.*	45,500	254,800
Digi International, Inc.*	13,200	319,704
Inuvo, Inc.*	514,500	254,677
Perficient, Inc.*	5,700	522,633
		<u>1,590,524</u>
9.96% SOFTWARE SERVICES		
Asure Software, Inc.*	36,000	205,200
ePlus, Inc.*	12,000	637,440
		<u>842,640</u>
95.21% TOTAL COMMON STOCKS		<u>8,055,436</u>
4.94% SHORT-TERM INVESTMENTS		
Fidelity Investments Money Market Government Portfolio Institutional Class 1.21%**	417,450	<u>417,450</u>
100.15% TOTAL INVESTMENTS		8,472,886
(0.15%) Liabilities in excess of other assets		(12,464)
100.00% NET ASSETS		<u><u>\$ 8,460,422</u></u>

* Non-income producing

** Effective 7 day yield as of June 30, 2022

PERKINS DISCOVERY FUND

Schedule of Investments - continued

June 30, 2022 (unaudited)

In accordance with U.S. GAAP, “fair value” is defined as the price that a Fund would receive upon selling an investment in an orderly transaction to an independent buyer in the principal or most advantageous market for the investment. Various inputs are used in determining the value of a Fund’s investments. U.S. GAAP established a three-tier hierarchy of inputs to establish a classification of fair value measurements for disclosure purposes. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). Level 3 includes significant unobservable inputs (including the Fund’s own assumptions in determining fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund’s investments as of June 30, 2022:

	Level 1	Level 2	Level 3	
		Other		
		Significant	Significant	
		Observable	Unobservable	
	Quoted Prices	Inputs	Inputs	Total
Common Stocks	\$ 8,055,436	\$ —	\$ —	\$ 8,055,436
Short-Term Investments	417,450	—	—	417,450
Total Investments	\$ 8,472,886	\$ —	\$ —	\$ 8,472,886

The Fund held no Level 3 securities at any time during the period.

There were no transfers into or out of Levels 1 and 2 during the period ended June 30, 2022.

At June 30, 2022, the cost of investments for Federal income tax purposes has been estimated since the final tax characteristics cannot be determined until fiscal year end. Cost of securities for Federal income tax purpose is \$7,126,763 and the related tax-based net unrealized appreciation (depreciation) consists of:

Gross unrealized appreciation	\$ 3,792,899
Gross unrealized depreciation	(2,446,776)
Net unrealized appreciation	\$ 1,346,123

